IL-22BP production is heterogeneously distributed in Crohn’s disease

• DOI: 10.3389/fimmu.2022.1034570
• Publication Date: 2022-10-13T07:06:03Z
• Authors: Aurélie Fantou; Eric Lagrue; Thomas Laurent; Laurence Delbos; Stéphanie Blandin; Anne Jarry; Gaëlle Beriou; Cécile Braudeau; Nina Salabert; Eros Marin; Aurélie Moreau; Juliette Podevin; Arnaud Bourreille; Régis Josien; Jérôme C. Martin
• Keywords: Monocyte

Crohn’s disease (CD), a form of inflammatory bowel (IBD), is characterized by impaired epithelial barrier functions and dysregulated mucosal immune responses. IL-22 binding protein (IL-22BP) soluble inhibitor regulating bioactivity, cytokine proposed to play protective roles during CD. We others have shown that IL-22BP produced in IBD inflamed tissues, hence suggesting role In this work, we extended the characterization production distribution CD tissues applying enzyme-linked immunosorbent assays supernatants obtained from culture endoscopic biopsies patients, reverse transcription-quantitative polymerase chain reaction on sorted cell subsets. reveal levels are higher ileums than colons. observe cell-intrinsic fashion, populations mononuclear phagocytes eosinophils express at highest comparison other sources T cells. suggest enrichment intestinal could explain ileum. colon, presence increased IL-22/IL22BP ratios compared controls, strong correlation between CCL24. identify monocyte-derived dendritic cells (moDC) as cellular subtype co-expressing both cytokines validate our finding using vitro systems. also show retinoic acid induces secretion CCL24 moDC. Finally, report active smokers. conclusion, work provides new information relevant therapeutic strategies modulating bioactivity CD, especially context location.